News Archives

05/08/2015

 

Exploring the genetic foundations of human behaviour

Award winning story reveals how big data sheds new light on the human brain

 

Montreal May 08, 2015 — Autism can be an all too obvious condition to identify but its underlying cause remains a mystery. Now tantalizing clues are starting to emerge from an ambitious project that has been collecting detailed genetic information about how the brain develops and functions. Researchers at Toronto’s Hospital for Sick Children have been mining the massive database created for the Brainspan Atlas, which is an American initiative to map the human brain’s biochemical activity to an unprecedented degree. Their findings have established new links between a key set of genes and the appearance of Autism Spectrum Disorder (ASD).

 

In fact, these unique genetic features may represent even more than the roots of ASD. They could be the distinguishing characteristic of modern human beings, the core of what makes us different from now extinct relatives such as Neanderthals as well as non-human primates. In this way we may finally be able to understand our evolutionary nature even as we learn to deal with how problems like autism conflict with that nature.

 

Globe and Mail science writer Ivan Semeniuk travelled to the Seattle headquarters of the Brainspan Atlas in order to assemble a feature story about this project. The resulting article, “The Hunt for Humanity”, is being honoured with this year’s Sanofi Pasteur Medal of Excellence in Health Research Journalism.

 

“This is a high quality report,” said one of the award judges, referring to Semeniuk’s account of the work to determine which genes were active during a human being’s fetal development. Another judge highlighted the clear explanation of how big data, imaging and genetic analysis together explained ASD in evolutionary terms.

 

CHR Past President Patricia Guyda adds that it would be satisfying enough to gain insight into the nature of ASD. “However, this research also offers us an extraordinary perspective on who we are as a species,” she says. “This is an outstanding example of why we should continue to support science dedicated to discovery as well as applied solutions.”

 

CHR launched the Sanofi Pasteur Medal of Excellence in Health Research Journalism in 1995, and administers the selection process. Sponsored by Sanofi Pasteur Limited, Canada's premier vaccine company, the inaugural medal recipient was Globe & Mail science reporter Stephen Strauss for his longstanding contribution to promoting public awareness of science. Other recent awardees include Paul Webster for his work in Vancouver Magazine, Marine Corniou for her work in Québec Science magazine and François Bouthillette a journalist at Radio-Canada.

 

“As a company that is built on over a century of science, Sanofi Pasteur is pleased to be associated with this prestigious award that recognizes excellence in science journalism,” says Nancy Simpson, Director, Communications at Sanofi Pasteur Limited.

 

As part of the award, Semeniuk will receive a plaque and a $2,500 bursary on June 20, 2015, during the Canadian Science Writers’ Association annual general meeting in Saskatoon.

 

Canadians for Health Research (CHR) is a nonprofit organization committed to promoting the stability and quality of Canadian health research.  It fosters communication between health researchers, the government and the Canadian public, and publishes a quarterly magazine entitled Future Health.  For more information, or to become a member, please visit the CHR website at http://www.chrcrm.org.

 

About Sanofi

 

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.ca

 

For more information, please contact:

 

Patricia Guyda                                                Nancy Simpson                     

CHR                                                                Director, Communications

Montreal, QC                                                 Sanofi Pasteur Limited

                                                                        Toronto, Ontario

514-398-7478                                                  416-667-2955

pguyda@chrcrm.org                                      nancy.simpson@sanofipasteur.com

chrpat@videotron.ca

 

11/19/2014

 

Toronto, November 19, 2014 – Today Russell Williams, President of Canada’s Research-Based Pharmaceutical Companies (Rx&D), is pleased to announce the creation of the J. Mark Lievonen Scholarship in Health Industry Management at the Schulich School of Business (Schulich) at York University, during the association’s first-ever stakeholder conference celebrating its 100th-year anniversary.

“As the demand grows for strong and skilled healthcare management professionals, Rx&D is proud to further strengthen the link between industry and Canada’s top academic centres,” said Russell Williams.

The scholarship has been established in recognition of Mark Lievonen, President of Sanofi Pasteur Limited and outgoing Chair of the Rx&D Board.

“The J. Mark Lievonen scholarship is a tremendous vote of confidence by industry leaders in Schulich’s MBA students, who are preparing to become Canada’s next generation of leaders within this country’s vitally important health industry,”  said Brenda Zimmerman, Director of Schulich’s Health Industry Management Program.

The J. Mark Lievonen Scholarship will provide a second-year Master of Business Administration or International Master of Business Administration student in the Schulich Health Industry Management Program with a scholarship of approximately $7,000 to further their studies in the program. Rx&D and Sanofi Pasteur Limited have each contributed $25,000, and Mark Lievonen has contributed an additional $25,000. Schulich will match the annual income generated by their contributions, effectively creating an endowment valued at $150,000.

“As an alumnus of York, I am proud to be able to further the success of Schulich’s Health Industry Management Program,” said Mark Lievonen. “We recognize the need to prepare the best and brightest minds to take leadership roles in Canada’s healthcare sector.”

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada’s knowledge-based economy, contributing over $3 billion to the Canadian economy.  Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

– 30 –

For further information:

Sarah Douglas
Media Relations, Rx&D
Telephone: 613-236-0455 extension 525
E-mail: sdouglas@canadapharma.org

11/19/2014

TORONTO, ON – Wednesday, November 19, 2014 – The Schulich School of Business at York University is pleased to announce the establishment of the J. Mark Lievonen Scholarship for MBA students enrolled in the School’s Health Industry Management Program (HIMP), which celebrates its 10th anniversary this year.

The J. Mark Lievonen Scholarship was established by Sanofi Pasteur Limited and Canada’s Research-Based Pharmaceutical Companies (Rx&D) to honour Mr. Lievonen’s exceptional leadership and contributions to the health and pharmaceutical sectors. Mr. Lievonen, BBA’79, MBA’87, is currently President of Sanofi Pasteur Limited and Chair of the Board of Directors for Rx&D and was recently honoured for his Outstanding Public Contribution at Schulich’s 2014 Alumni Recognition Awards. Lievonen has also made a generous gift towards the establishment of the scholarship.  

The annual scholarship, which will award approximately $7,000 to a second-year MBA student enrolled in Schulich’s Health Industry Management Program, is being announced at a first-ever stakeholder conference being organized by Rx&D. Rx&D and Sanofi Pasteur Limited have each contributed $25,000, and Mark Lievonen has contributed an additional $25,000. York University will match the annual income generated by their contributions, effectively creating an endowment valued at $150,000.

“The J. Mark Lievonen scholarship is a tremendous vote of confidence by industry leaders in Schulich’s MBA students, who are preparing to become Canada’s next generation of leaders within this country’s vitally important health industry,”  said Brenda Zimmerman, Director of Schulich’s Health Industry Management Program. “We especially appreciate this important industry investment in our students as Schulich’s HIMP program celebrates its 10th anniversary.”

Since 2004, more than 300 MBA students have graduated from Schulich’s  Health Industry Management Program, which prepares students for leadership careers in public, private and non-profit sectors within the complex, rapidly growing industry, both in Canada and globally.  

“As an alumnus of York, I am proud to be able to further the success of Schulich’s Health Industry Management Program,” said Mark Lievonen, BBA ’79, MBA ’87, president of Sanofi Pasteur Limited and Chair of the Board of Directors for Rx&D.  “We recognize the need to prepare the best and brightest minds to take leadership roles in Canada’s healthcare sector.”

“Schulich is proud to be able to offer this scholarship in honour of one of Canada’s foremost health industry executives and one of our School’s most successful graduates,” said Schulich Dean Dezsö J. Horváth. “Any student of business, and especially those planning a career in health industry management, would do well to follow the excellent example of Mark Lievonen.”

The HIMP specialization provides students advanced standing towards earning their Certified Health Executive (CHE) designation, Canada’s only professional credential available to health leaders, under the Schulich School of Business’ strategic alliance with the Canadian College of Health Leaders (CCHL).

 

About Schulich

Known as Canada’s Global Business School™, the Schulich School of Business in Toronto is ranked among the world’s leading business schools by a number of global surveys. Schulich’s MBA program is ranked #1 in the world by Corporate Knights, the world’s largest circulation magazine with an explicit focus on Corporate Social Responsibility, and #2 in the world by the Aspen Institute (a Washington, DC-based leadership think tank) in global surveys that identify which schools are doing the best job of preparing future business leaders for the environmental, social and ethical complexities of modern-day business. Schulich’s MBA program is also ranked among the world’s leading schools by The Economist, Forbes, Bloomberg Businessweek and Expansión, Mexico’s leading business publication. The Kellogg-Schulich EMBA program is ranked #1 in the world by The Economist, and #1 in Canada by the Financial Times of London. For complete ranking details, please visit www.schulich.yorku.ca.

Global, innovative and diverse, Schulich offers business programs year-round at its state-of-the-art complex at York University; at its Miles S. Nadal Management Centre located in the heart of the Toronto’s financial district; and at its new campus in Hyderabad, India. Schulich also operates a number of satellite centres in Beijing and Shanghai, China; Mumbai, India; Seoul, South Korea; Mexico City, Mexico; and Sao Paulo, Brazil. Schulich offers undergraduate, graduate and postgraduate business degrees that lead to rewarding careers in the private, public and nonprofit sectors, and has 27,000 alumni working in over 90 countries. The School pioneered Canada’s first International MBA (IMBA) and International BBA (iBBA) degrees, as well as North America’s first ever cross-border executive MBA degree, the Kellogg-Schulich Executive MBA. In addition to Schulich’s Master of Finance and Master of Accounting degrees, the School recently launched one of the world’s first Master of Business Analytics degrees. Schulich’s Executive Education Centre provides executive development programs annually to more than 10,000 executives in Canada and abroad.

 

About Mark Lievonen

Mark Lievonen is President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. Under his leadership, Sanofi Pasteur has become a billion dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets.

Mr. Lievonen is a Director of Oncolytics Biotech Inc., Chair, Canada’s Research-Based Pharmaceutical Companies (Rx&D), Vice-Chair of the Ontario Institute for Cancer Research, and serves on the Boards of the Public Policy Forum, BIOTECanada and the Markham Stouffville Hospital Foundation.

He is a past Chair of the Ontario Genomics Institute, BIOTECanada, the Markham Stouffville Hospital Foundation, the Centre for the Advancement of Health Innovations and the Steering Committee for the BIO 2002 International Conference. He served on the York University Board of Governors, and is a former director of Markham Stouffville Hospital and YORKbiotech.

Mr. Lievonen was a Co-Chair of the Ontario-Quebec Private Sector Advisory Committee and was a member of the Ontario Investment and Trade Advisory Council, the BIOCouncil, and the Toronto Mayor’s Economic Competitiveness Advisory Committee. He served as a member of the United Way of Greater Toronto Cabinet, chairing the Health Care Division.

He holds a BBA in accounting and an MBA in finance and marketing from the Schulich School of Business, York University. He is a Chartered Accountant and received his designation while working with PricewaterhouseCoopers.

Mr. Lievonen was the recipient of a Queen’s Golden Jubilee Medallion in 2002, was named a Chevalier de l'Ordre National de Mérite by the government of France in 2007 and received the Queen’s Diamond Jubilee Medal in 2012. He was elected a Fellow of the Institute of Chartered Accountants of Ontario in 2009 and was inducted into the Canadian Healthcare Marketing Hall of Fame in 2013. In 2014, Mr. Lievonen received the Life Sciences Ontario Lifetime Achievement Award.

 

For more information, please contact:

Brenda Zimmerman, Director
Health Industry Management Program
Associate Professor of Strategic Management/Policy
Schulich School of Business
Phone: 416-736-2100, ext. 33357
Email: bzimmerman@schulich.yorku.ca

05/23/2014

 

2014 Sanofi BioGENEius Challenge Canada (SBCC) Highlights Newest Crop of Young Scientists

 

OTTAWA, May 23, 2014 – A novel method of HIV detection for newborns under the age of 18 months and for adults before three months post-transmission earned a grade 10, British Columbia student top national honours today in the 2014 “Sanofi BioGENEius Challenge Canada” (SBCC).

 

Nicole Ticea, 15, from York House School in Burnaby, BC was awarded the top prize of $5,000 by a panel of eminent Canadian scientists assembled at the Ottawa headquarters of the National Research Council of Canada (NRC). 

 

Her impressive research project, mentored at Simon Fraser University by associate professor, Dr. Mark Brockman, is the first test capable of analyzing HIV viral nucleic acids in a point-of-care, low-resource setting. Nicole’s research, was deemed an incredibly innovative solution to a global challenge according to the judges led by Dr. Julie Ducharme, General Manager, Human Health Therapeutics, NRC.

See a full project description below and online here: http://sanofibiogeneiuschallenge.ca/2014/05/23/

 

Ten brilliant young scientists from nine Canadian regions, all just 15 to 18 years old, took part in the national finals. They had placed first at earlier regional SBCC competitions, conducted between March 27 and May 22, 2014.

 

High school and CEGEP students from Victoria to Saskatoon to St. John’s, focused on biotechnology fields of discovery and study, submitted more than 200 proposals. Working closely with mentors, these students conducted research in diverse areas such as telomeres, diabetes, stress management, Alzheimer’s, autism and pulp production. Since its inauguration in 1994, more than 4,700 young Canadians have competed in SBCC, with the majority of competitors going on to pursue careers in science and biotechnology.

 

1st place winner, Nicole Ticea will compete for Canada on June 22-25 at the International BioGENEius Challenge, conducted at the annual BIO conference in San Diego, CA.

 

2nd place, $4,000 – Ontario: Varsha Jayasankar, 17, grade 12, Sir Winston Churchill Secondary School, St. Catherines won with research into how an extract created from mango ginger can be used to inhibit the growth of multiple antibiotic-resistant bacteria. Project description: http://sanofibiogeneiuschallenge.ca/2014/05/23/

 

3rd place, $3,000 – Ontario: Anoop Manjunath, 17, grade 11, University of Toronto Schools, Toronto investigated image processing techniques for the analysis of ultrasound stimulated bubble interactions with fibrin clots. Project description: http://sanofibiogeneiuschallenge.ca/2014/05/23/

 

4th place, $2,000 – Manitoba: Ryan Wang,18, grade 12, St. John’s-Ravenscourt School, Winnipeg, found that a protein called scleraxis is directly involved in cardiac fibrosis, which is characterized by the stiffening of the heart muscles. Project description: http://sanofibiogeneiuschallenge.ca/2014/05/23/

 

5th place, $1,000 – Quebec: Julien Sénécal, 18, 1st year CEGEP, Collège Jean-de-Brébeuf, Montreal, used the defense system of the Streptococcus pyogenes bacteria to inhibit the replication of HIV-1) Project description: http://sanofibiogeneiuschallenge.ca/2014/05/23/

    

SBCC 2014 National Winners, from left to right: Julien Sénécal, Varsha
Jayasankar, Anoop Manjunath, Nicole Ticea, & Ryan Wang.

 

Sanofi Canada President and CEO Jon Fairest, who presented the top national prize, said, "The Sanofi Group is very proud to be founding sponsors of the Sanofi BioGENEius Challenge Canada and participate in this inspiring competition. With its 21-year heritage, the SBCC shows how critical partnerships are to advance science and talent in Canada. From the mentoring provided by dedicated academics, to the support of government and the private sector, the SBCC truly stands out as a model for collaboration. The program is one response to Canada’s national priority of encouraging skills development, education and jobs in STEM (Science, Technology, Engineering and Mathematics) fields.”

 

The SBCC gives young scientists access to professional labs and academic mentors, encouraging the pursuit of future studies and careers in the country’s fast-growing biotechnology sector.

 

Each of the students worked for months conducting research and collaborating with university mentors.

 

1st Place Project Title: Isothermal Nucleic Acid Amplification System for Point-of-Care HIV Diagnosis. The project presents a novel method of HIV detection in developing countries. The test is capable of diagnosing HIV in newborns under the age of 18 months and for adults before three months post-transmission. It is the first test capable of analyzing HIV viral nucleic acids in a point-of-care, low-resource setting.

 

The nine final national projects were presented at NRC headquarters Friday, May 23 to a panel of eminent Canadian scientists:

  • Dr. Julie Ducharme, General Manager, Human Health Therapeutics, National Research Council
  • Dr. Pierre Meulien, President, Genome Canada
  • Ms. Jessie McAlpine, SBCC Alumna, Student at University of Toronto
  • Dr. Jim Richards, Director, Better Vaccine High-Risk Population, Human Health Therapeutics, National Research Council
  • Dr. Robert Tsushima, Associate Dean, Research and Partnerships, Faculty of Science, York University



 

National Awards Presenters included :

 

  • MC – Senator Joseph A. Day
  • MC – Denise  Amyot, President and ceo of the Association of Canadian Community Colleges
  • VROC Expert Participation Awards – Brent Peltola
  • SBCC commercialization Award – Karimah Es Sabar, CEO and president of the Centre for Drug Research and Development
  • 5th Place - Ms. Jessie MacAlpine, SBCC alumna
  • 4th Place - Pierre Meulien, Genome Canada
  • 3rd Place - Dr. Jim Richards, NRC
  • 2nd Place - Kevin Cougler, Partners In Research
  • 1st Place– Jon  Fairest, Sanofi Canada President and CEO

 

 

About the Sanofi BioGENEius Challenge Canada (SBCC)

The Sanofi BioGENEius Challenge Canada (SBCC) is a national, biotechnology research competition that encourages high school and CEGEP students to pursue future studies and careers in the exciting field of biotechnology. Coordinated by Partners In Research, the initiative is sponsored by Sanofi Pasteur Limited, Sanofi Canada, the Ontario Government (Ministry of Research & Innovation), York University, the National Research Council Canada/Conseil national de recherches Canada (NRC-CNRC), Canadian Institutes of Health Research/Instituts de recherche en santé du Canada (CIHR-IRSC) and Genome Canada.

-30-

 

Media Contacts:

Andrea Mancini

CASACOM

amancini@casacom.ca

Tel: 416-944-2145

 

Anne Ramsay

Partners In Research

aramsay@pirweb.org

Tel: 519-433-7866

 

For more information, please visit www.sanofibiogeneiuschallenge.ca, follow us on Facebook or Twitter at https://twitter.com/@SBCCDBSC hashtag: #SBCC2014

05/13/2014

 

21st annual SBCC National Awards take place in Ottawa on May 23, 2014

 

 

TORONTO, ON, May 13, 2014 – After months of preparation, research and collaboration with top university mentors, an elite group of 10 young scientists from across the country will be in Ottawa May 22, 2014 competing for Canada’s ultimate student biotechnology science prizes in the 2014 Sanofi BioGENEius Challenge Canada (SBCC).

 

Over 4,700 high school and CEGEP students have participated in the “Sanofi BioGENEius Challenge Canada” since its inception 21 years ago. The SBCC varies from other science competitions as students are given access to high quality lab equipment and are paired with mentors. For the last 21 years, the competition has been giving aspiring young scientists the chance to develop research that can lead them towards a career in science, making it a win for all of those involved.

 

The National SBCC Awards ceremony will be held on May 23, 2014, at 7pm EDT, at the Ottawa Conference and Event Centre.

 

In total judges chose nine cutting-edge biotechnology research projects from the 126 projects that competed across Canada.  Now in its 21th year, the SBCC gives young scientists access to university labs and academic mentors, encouraging the pursuit of future studies and careers in the country’s fast-growing biotechnology sector. 

 

"Even after more than 20 years of the SBCC, I am simply astounded by the life-changing discoveries that these young students make, and the power of science,” said Mark Lievonen, President, Sanofi Pasteur Limited, which originally founded the event. “Thanks to the collaboration between industry, government and academia, the SBCC fosters a culture of innovation in Canada, ultimately accelerating Canadian competitiveness and productivity. Programs like this are essential to shaping and cultivating the next generation of leaders.”

 

This year’s regional finalists:

 

  • Nicole Ticea, York House School, Vancouver, BC, “Isothermal Nucleic Acid Amplification System for Point-of-Care HIV Diagnosis”
  • Jessica Wickware, Harry Ainlay High School, Edmonton, AB, “Tumor Origami: A Three-Dimensional Visualization of Drug Resistance in Malignant Tumors”
  • Amy Wang & WenYu Ruan, Walter Murray Collegiate, Saskatoon, SK, “Identification of Leaf Rust Resistance in Wheat”
  • Ryan Wang, St. John’s Ravenscourt School, Winnipeg, MB, “Identification and functional characterization of putative phosphorylation sites on scleraxis”
  • Varsha Jayasankar, Sir Winston Churchill Secondary School, St. Catharines, ON, “Identification of Novel Broad-Spectrum Antimicrobial Compounds in Curcuma Amada”
  • Anoop Manjunath, University of Toronto Schools, Toronto, ON, “Image Processing Techniques for the Analysis of Ultrasound Stimulated Bubble Interactions with Fibrin Clots”
  • Amit Scheer, Colonel By Secondary School, Ottawa, ON, “Development of a Novel Quantum Dot-Aptamer Bioconjugate Targeted Cancer Therapy for Precision Nanomedicine Applications”
  • Julien Sénécal, Collège Jean-de-Brébeuf, Montreal, QC, “Inhibition of HIV-1 Replication Cycle with the CRISPR/Cas9 System”
  • Mark Hewitt, Bishops College High School, St. John’s, NFLD, “Can Popular Acne Treatments Stimulate or Exacerbate Cancer Growth?”

 

The project finalists will be judged on May 22, 2014 at the headquarters of the National Regional Council by a panel of pre-eminent Canadian scientists:

 

  • Dr. Julie Ducharme, General Manager, Human Health Therapeutics, National Research Council
  • Dr. Pierre Meulien, President, Genome Canada
  • Ms. Jessie McAlpine, SBCC Alumna, Student at University of Toronto
  • Dr. Jim Richards, Director, Better Vaccine High-Risk Population, Human Health Therapeutics, National Research Council
  • Dr. Robert Tsushima, Associate Dean, Research and Partnerships, Faculty of Science, York University

 

In addition to their regional competition winnings, Canada’s 1st, 2nd, 3rd, 4th and 5th place national winners will receive $5,000, $4,000, $3,000, $2,000 and $1,000 respectively.  A special $1,000 prize is awarded to the project deemed by the judges to have the greatest commercial value. The top single person project advances to the Sanofi-sponsored International BioGENEius Challenge to be held in San Diego, CA June 20-24, 2014, in conjunction with the BIO Annual International Convention.

 

About the Sanofi BioGENEius Challenge Canada (SBCC)

The Sanofi BioGENEius Challenge Canada (SBCC) is a national, biotechnology research competition that encourages high school and CEGEP students to pursue future studies and careers in the exciting field of biotechnology. Coordinated by Partners In Research, the initiative is sponsored by Sanofi Pasteur Limited, Sanofi Canada, the Ontario Government (Ministry of Research & Innovation), York University, the National Research Council Canada/Conseil national de recherches Canada (NRC-CNRC), Canadian Institutes of Health Research/Instituts de recherche en santé du Canada (CIHR-IRSC) and Genome Canada.

 

For more information, please visit www.sanofibiogeneiuschallenge.ca, follow us on Facebook or Twitter at https://twitter.com/@SBCCDBSC hashtag: #SBCC2014

 

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.ca.

 

 

-30-

 

 

Media Contacts:

 

Andrea Mancini

CASACOM

amancini@casacom.ca

Tel: 416-944-2145

 

Anne Ramsay

Partners In Research

aramsay@pirweb.org

Tel: 519-433-7866

 

 

Pages